Overview
US state regulatory sandboxes allowing controlled pilots of AI in clinical workflows — particularly prescription refills — under structured oversight rather than outright approval or ban.
Utah Doctronic Pilot (2026)
- OAIP regulatory mitigation agreement; Phase 1 requires 100% physician review
- 192-drug maintenance formulary; no controlled substances
- Medical board opposition; FDA has not authorized AI chatbots for prescriptions
- Expansion bills in Texas, Wyoming, Cicero Institute-backed states
Policy Tension
Sandboxes test real-world performance under oversight but efficacy data may be company-authored. Federal FDA jurisdiction vs. state practice-of-medicine framing remains unresolved (2026-07-06-utah-doctronic-ap-news).